The prion protein binds thiamine

Although highly conserved throughout evolution, the exact biological function of the prion protein is still unclear. In an effort to identify the potential biological functions of the prion protein we conducted a small‐molecule screening assay using the Syrian hamster prion protein [shPrP(90–232)]. The screen was performed using a library of 149 water‐soluble metabolites that are known to pass through the blood–brain barrier. Using a combination of 1D NMR, fluorescence quenching and surface plasmon resonance we identified thiamine (vitamin B1) as a specific prion ligand with a binding constant of ∼ 60 μm. Subsequent studies showed that this interaction is evolutionarily conserved, with similar binding constants being seen for mouse, hamster and human prions. Various protein construct lengths, both with and without the unstructured N‐terminal region in the presence and absence of copper, were examined. This indicates that the N‐terminus has no influence on the protein’s ability to interact with thiamine. In addition to thiamine, the more biologically abundant forms of vitamin B1 (thiamine monophosphate and thiamine diphosphate) were also found to bind the prion protein with similar affinity. Heteronuclear NMR experiments were used to determine thiamine’s interaction site, which is located between helix 1 and the preceding loop. These data, in conjunction with computer‐aided docking and molecular dynamics, were used to model the thiamine‐binding pharmacophore and a comparison with other thiamine binding proteins was performed to reveal the common features of interaction.

[1]  Eric Oldfield,et al.  1H, 13C and 15N chemical shift referencing in biomolecular NMR , 1995, Journal of biomolecular NMR.

[2]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[3]  S. Hornemann,et al.  Prion protein NMR structure from tammar wallaby (Macropus eugenii) shows that the beta2-alpha2 loop is modulated by long-range sequence effects. , 2009, Journal of molecular biology.

[4]  U. Agrimi,et al.  Advances in scrapie research. , 2007, Revue scientifique et technique.

[5]  Charles D Schwieters,et al.  The Xplor-NIH NMR molecular structure determination package. , 2003, Journal of magnetic resonance.

[6]  M. Moudjou,et al.  Cellular prion protein status in sheep: tissue-specific biochemical signatures. , 2001, The Journal of general virology.

[7]  Frank Baumann,et al.  Axonal prion protein is required for peripheral myelin maintenance , 2010, Nature Neuroscience.

[8]  Egon L. Willighagen,et al.  The Blue Obelisk—Interoperability in Chemical Informatics , 2006, J. Chem. Inf. Model..

[9]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[10]  L. Schonberger,et al.  Variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. , 2002, Clinics in laboratory medicine.

[11]  J. Berger Kuru in the 21st century—an acquired human prion disease with very long incubation periods , 2008 .

[12]  D. Harris,et al.  The cellular prion protein (PrP(C)): its physiological function and role in disease. , 2007, Biochimica et biophysica acta.

[13]  D. Westaway,et al.  The prion protein family: diversity, rivalry, and dysfunction. , 2007, Biochimica et biophysica acta.

[14]  Constance A. Sobsey,et al.  Detailed biophysical characterization of the acid-induced PrP(c) to PrP(β) conversion process. , 2011, Biochemistry.

[15]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[16]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[17]  F. Cohen,et al.  Cryptic epitopes in N‐terminally truncated prion protein are exposed in the full‐length molecule: Dependence of conformation on pH , 2001, Proteins.

[18]  F. Chantraine,et al.  Thiamine Status in Humans and Content of Phosphorylated Thiamine Derivatives in Biopsies and Cultured Cells , 2010, PloS one.

[19]  J. Collinge,et al.  Location and properties of metal-binding sites on the human prion protein , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Bruce A Johnson,et al.  Using NMRView to visualize and analyze the NMR spectra of macromolecules. , 2004, Methods in molecular biology.

[21]  D. Lütjohann,et al.  Simvastatin prolongs survival times in prion infections of the central nervous system. , 2006, Biochemical and biophysical research communications.

[22]  Iva Hafner-Bratkovič,et al.  Curcumin binds to the α‐helical intermediate and to the amyloid form of prion protein – a new mechanism for the inhibition of PrPSc accumulation , 2008 .

[23]  J. Collinge,et al.  Pharmacological chaperone for the structured domain of human prion protein , 2010, Proceedings of the National Academy of Sciences.

[24]  G. Forloni,et al.  Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. , 2000, Journal of molecular biology.

[25]  G. J. Raymond,et al.  Hemin Interactions and Alterations of the Subcellular Localization of Prion Protein* , 2007, Journal of Biological Chemistry.

[26]  E. Walter,et al.  The affinity of copper binding to the prion protein octarepeat domain: evidence for negative cooperativity. , 2006, Biochemistry.

[27]  D. Lonsdale A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(e) and Its Derivatives , 2006, Evidence-based complementary and alternative medicine : eCAM.

[28]  K. Jellinger,et al.  Fatal familial insomnia: a new Austrian family. , 1999, Brain : a journal of neurology.

[29]  B. Meyer,et al.  Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. , 2001, Journal of the American Chemical Society.

[30]  F E Cohen,et al.  Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  K. Fiebig,et al.  Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein. , 2003, Journal of medicinal chemistry.

[32]  X. Xi,et al.  Thermodynamic analysis of fluorescence enhancement and Quenching theory equations , 2008 .

[33]  B. Caughey,et al.  Prions and their partners in crime , 2006, Nature.

[34]  V. Barone,et al.  Assessing the acid–base and conformational properties of histidine residues in human prion protein (125–228) by means of pKa calculations and molecular dynamics simulations , 2006, Proteins.

[35]  V. Ganapathy,et al.  SLC19: the folate/thiamine transporter family , 2004, Pflügers Archiv.

[36]  J. Lakowicz Principles of fluorescence spectroscopy , 1983 .

[37]  John Collinge,et al.  Kuru in the 21st century—an acquired human prion disease with very long incubation periods , 2006, The Lancet.

[38]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[39]  A. Schmidtchen,et al.  Antimicrobial Activity of Human Prion Protein Is Mediated by Its N-Terminal Region , 2009, PloS one.

[40]  M. Miller,et al.  Chronic wasting disease of cervids. , 2004, Current topics in microbiology and immunology.

[41]  M. Álvarez-Martínez,et al.  Physiological role of the cellular prion protein. , 2008, Veterinary research.

[42]  R. Davis,et al.  Protein binding of thiamin in human plasma. , 1986, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

[43]  Andrea Didier,et al.  Tissue-specific expression pattern of bovine prion gene: quantification using real-time RT-PCR. , 2003, Molecular and cellular probes.

[44]  S. V. Anisimov,et al.  Congo red and protein aggregation in neurodegenerative diseases , 2007, Brain Research Reviews.